Alveolar soft part sarcoma

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA

Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
3 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


All lines of therapy

Atezolizumab monotherapy

Regimen variant #1, q3wk

FDA-recommended dose
Study Dates of enrollment Evidence
Chen et al. 2023 (Study ML39345) 2017-04 to 2022-07 Phase 2 (RT)


  • Atezolizumab (Tecentriq) by the following age-based criteria:
    • 18 years old or older: 1200 mg IV once on day 1
    • Younger than 18 years old: 15 mg/kg (maximum dose of 1200 mg) IV once on day 1

21-day cycles

Regimen variant #2, q2wk

FDA-recommended dose


14-day cycles

Regimen variant #3, q4wk

FDA-recommended dose


28-day cycles


  1. Study ML39345: Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 7;389(10):911-921. link to original article contains dosing details in abstract PubMed NCT03141684